Rectal 5‐ASA showed no clear difference in endoscopic remission compared with oral 5‐ASA (low certainty).
Once daily dosing showed no clear difference in failure to induce global or clinical remission compared with conventional dosing (high certainty).
Once daily dosing showed no clear difference in failure to induce global or clinical improvement compared with conventional dosing (moderate certainty).
Once daily dosing showed no clear difference in failure to induce endoscopic remission compared with conventional dosing (high certainty).
Once daily dosing showed no clear difference in failure to adhere to medication regimen compared with conventional dosing (low certainty).
Once daily dosing showed no clear difference in adverse events compared with conventional dosing (moderate certainty).
Once daily dosing showed no clear difference in serious adverse events compared with conventional dosing (low certainty).
Once daily dosing showed no clear difference in withdrawal due to adverse events compared with conventional dosing (low certainty).
Once‐daily dosing showed no clear difference in failure to maintain clinical or endoscopic remission compared with conventional dosing (high certainty).
Once‐daily dosing showed no clear difference in failure to adhere to study medication regimen compared with conventional dosing (moderate certainty).
Once‐daily dosing showed no clear difference in adverse event compared with conventional dosing (high certainty).
Once‐daily dosing showed no clear difference in serious adverse events compared with conventional dosing (moderate certainty).
It is very uncertain whether once‐daily dosing changes withdrawal due to adverse events compared with conventional dosing (very low certainty).
Once‐daily dosing showed no clear difference in exclusion/withdrawal after entry compared with conventional dosing (high certainty).
5‐ASA showed no clear difference in clinical relapse compared with no treatment (low certainty).
The review found no eligible studies for this question.
5‐ASAs showed no clear difference in adverse events compared with placebo (low certainty).
5‐ASAs showed no clear difference in serious adverse events compared with placebo (low certainty).
5‐ASAs showed no clear difference in withdrawal due to adverse events compared with placebo (low certainty).
The review found no eligible studies for this question.